<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118689</url>
  </required_header>
  <id_info>
    <org_study_id>INK-128-002</org_study_id>
    <nct_id>NCT01118689</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia</brief_title>
  <official_title>A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
      and pharmacokinetics of MLN0128 in patients with Relapsed or Refractory Multiple Myeloma or
      Waldenstrom Macroglobulinemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the dose limiting toxicities</measure>
    <time_frame>28-days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Relapsed Multiple Myeloma</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>MLN0128</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN0128</intervention_name>
    <description>MLN0128 administered orally once daily for 28 days</description>
    <arm_group_label>MLN0128</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years, including males and females;

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;

          -  Life expectancy of ≥3 months;

          -  Does not have diabetes and has normal fasting serum glucose and fasting triglycerides
             ≤ 300 mg/dL

          -  For women of child-bearing potential, negative serum pregnancy test within 14 days
             prior to the first study drug administration and use of physician-approved method of
             birth control from 30 days prior to the first study drug administration to 30 days
             following the last study drug administration;

          -  Male subjects must be surgically sterile or must agree to use physician-approved
             contraception during the study and for 30 days following the last study drug
             administration;

          -  Ability to swallow oral medications;

          -  Ability to understand and willingness to sign informed consent form prior to
             initiation of any study procedures;

        Exclusion Criteria:

          -  Have received prior cancer therapy or other investigational therapy within 2 weeks
             prior to the first administration of study drug.

          -  Known impaired cardiac function or clinically significant cardiac disease

          -  HIV infection;

          -  Failed to recover from the reversible effects of prior anticancer therapies:

          -  Pregnancy (positive serum or urine pregnancy test) or breast feeding;

          -  Malabsorption due to prior gastrointestinal (GI) surgery, GI disease;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

